Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CANbridge Closes $98 Million D Round for Rare Disease/Oncology Portfolio

publication date: Feb 18, 2020

CANbridge Pharma, a Beijing biopharma developing products for orphan diseases and targeted cancers, closed a $98 million Series D financing led by General Atlantic and WuXi AppTec. Each of the two companies has the option to invest up to an additional $10 million. CANbridge has a global partnership with WuXi Biologics to develop novel therapeutics that treat rare genetic diseases. In January, CANbridge acquired China rights from South Korea's GC Pharma to commercialize Hunterase®, an enzyme replacement therapy for patients with Hunter syndrome. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020